Is One Year Enough? Extended Adjuvant Dabrafenib Plus Trametinib for Chinese Patients With Resected Stage <scp>III</scp> Melanoma
Extending dabrafenib plus trametinib beyond 1 year may provide improved RFS without increasing toxicity. Further prospective trials are warranted to confirm the impact on overall survival and identify optimal patient subsets for prolonged therapy.
Authors
- Linqing Li (ORCID: https://orcid.org/0000-0003-3003-9902)
- Zhiwei Ren (ORCID: https://orcid.org/0000-0001-9674-0588)
- Weitao Yao (ORCID: https://orcid.org/0000-0002-2963-8775)
- Tao Li (ORCID: https://orcid.org/0000-0002-5924-0522)
- Jilong Yang (ORCID: https://orcid.org/0000-0001-5162-3740)
- Xianan Li (ORCID: https://orcid.org/0000-0002-5872-9019)
- Lishu Lou
- Yu Xu (ORCID: https://orcid.org/0000-0001-7751-6345)
- Yong Chen (ORCID: https://orcid.org/0000-0002-7188-4566)
- Zhe Liu (ORCID: https://orcid.org/0000-0003-0726-2727)
- Dongdong Jia (ORCID: https://orcid.org/0000-0002-6804-4988)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-0045-6863)
- Yang Li (ORCID: https://orcid.org/0000-0002-7680-3374)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Hunan Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- The Journal of Dermatology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1111/1346-8138.17779
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.81